28.03.2018 curasan AG  DE0005494538

DGAP-News: curasan AG implements focused measures

DGAP-News: curasan AG / Key word(s): Miscellaneous curasan AG implements focused measures 28.03.2018 / 08:22 The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- - Persuasive expert symposium for physicians in Hamburg - New distribution partners in growth markets - Increase of brand awareness Kleinostheim, 28 March 2018 - curasan AG, Germany, a leading specialist for medical products in the field of orthobiologics, is currently busy with the bundled implementation of its announced intensified marketing and sales activities. Last weekend, the "1. Bone Regeneration Summit" took place at the University Hospital Hamburg-Eppendorf (UKE) with curasan acting as key sponsor. Under the patronage of the European Society of Tissue Regeneration in Orthopaedics and Traumatology (ESTROT), the UKE and the Institute for Osteology and Biomechanics (IOBM) 15 top-notch, international speakers from research, science and practice gave lectures during the CME accredited symposium. The presentations were about the latest findings in bone regeneration with a key focus on orthopedics, traumatology and spine surgery. A selection of the presentations will be published in the medical press in the following months thus becoming accessible to a larger group of medical professionals. Also in the dental segment curasan will be essentially involved as sponsor of another scientific event well-known to professional circles. On April 28, 2018, at the "Frankfurt Implantology Days", again, everything is about bone regeneration in dental implantology. The CME accredited event is titled with the motto "Science meets Practice". Renowned international experts will present their latest research results and case studies, giving helpful advice to the attending implantologists and oral surgeons. Furthermore, after taking over direct sales of its hyaluronic acid product CURASVISC(R) curasan AG is making considerable progress in the matter of osteoarthritis therapy in the DACH-countries. Only recently, the product has been registered in Switzerland and is finding an increasing number of users in Germany and Austria. Based on the cooperation between curasan and the "MercedesCup 2018" as well as the German-Austrian-Swiss Olympic Winter-Sports Physicians Congress, CURAVISC(R) is now also offered to competitive and leisure athletes with beginning symptoms of joint strains. "Besides increasing the awareness level of our brands, the strengthening of our sales structure in orthopedics occupies center stage", says Michael Schlenk, CEO of curasan AG. "In this context, we further expanded our global partner network systematically. Thus, we have gained additional new distribution partners in Europe only recently. In the Asia-Pacific region we now cooperate for Australia and New Zealand with a renowned partner with 25 years of experience in the local orthopedics and spine surgery market. With this measures, we put things on a promising track for our future sales growth." Contact curasan AG: Andrea Weidner Investor Relations & Corporate Communications +49 6027 40 900-51 ir@curasan.com About curasan AG: curasan develops, manufactures and markets biomaterials and medical devices in the field of bone and tissue regeneration, wound healing and osteoarthritis therapy. As a pioneer and global technology leader in the growing field of regenerative medicine, curasan is specialized primarily on biomimetic bone grafting materials for dental, oral/maxillofacial, orthopedic and spinal applications, i.e. materials mimicking biological structures. Numerous patents and a broad record of scientific publications demonstrate the clinical success of the products and the highly innovative strength of curasan. Dental and orthopaedic clinicians worldwide benefit from the broad range of the premium quality and easy to use portfolio offered by the technology leader curasan. curasan maintains its own high-tech facilities for research, development and manufacturing of biomaterials in Frankfurt/Main, Germany. In addition to its headquarters, the company has a subsidiary, curasan, Inc., in Wake Forest, near Raleigh, N.C., USA. curasan's innovative products are cleared by the US Food and Drug Administration (FDA) and many other international authorities and available in almost 50 countries worldwide. curasan AG is a public company listed in the General Standard at the Frankfurt Stock Exchange. --------------------------------------------------------------------------- 28.03.2018 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: curasan AG Lindigstraße 4 63801 Kleinostheim Germany Phone: 06027/40 900 0 Fax: 06027/40 900 29 E-mail: info@curasan.de Internet: www.curasan.de ISIN: DE0005494538 WKN: 549453 Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange End of News DGAP News Service --------------------------------------------------------------------------- 669545 28.03.2018

Die wichtigsten Finanzdaten auf einen Blick
  2012 2013 2014 2015 2016 2017 2018 2019e
Umsatzerlöse1 3,23 5,82 5,76 5,97 6,93 6,80 5,84 6,40
EBITDA1,2 -2,97 -1,64 -1,12 2,13 -2,14 -2,22 -3,84 -3,00
EBITDA-Marge3 -91,95 -28,18 -19,44 35,68 -30,88 -32,65 -65,75 -46,88
EBIT1,4 -3,32 -2,14 -1,83 1,33 -2,66 -2,84 -4,78 -2,80
EBIT-Marge5 -102,79 -36,77 -31,77 22,28 -38,38 -41,76 -81,85 -43,75
Jahresüberschuss1 -3,47 -2,14 -1,83 1,33 -2,09 -4,00 -5,38 -2,50
Netto-Marge6 -107,43 -36,77 -31,77 22,28 -30,16 -58,82 -92,12 -39,06
Cashflow1,7 -2,72 -1,85 -0,37 2,15 -2,11 -2,55 -4,34 0,00
Ergebnis je Aktie8 -1,53 -0,90 -0,72 0.45 -0,63 -0,99 -0,99 -0,33
Dividende8 0,00 0,00 0,00 0,00 0,00 0,00 0,00 0,00
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2018 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: Hinrik J. Schröder

WKN Kurs in € Einschätzung Börsenwert in Mio. €
549453 0,470 Verkaufen 4,26
KGV 2020e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
0,00 15,55 0,000 0,00
0,57 - 0,73 -1,204
Dividende '18 in € Dividende '19e in € Div.-Rendite '18
in %
0,00 0,00 0,00 26.06.2019
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
23.05.2019 22.08.2019 21.11.2019 13.05.2019
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
14,63% -17,54% -7,84% -48,91%
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu curasan AG  ISIN: DE0005494538 können Sie bei DGAP abrufen

Gesundheit , 549453 , CUR , XETR:CUR